TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07661329: A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

Sponsor: YS Life Science Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$990,024

Rescue Site Savings

+$660,016

Unlock Full NCT07661329 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07661329 Rescue Dossier →